Fly News Breaks for May 16, 2019
May 16, 2019 | 06:37 EDT
JPMorgan analyst Cory Kasimov keeps a Neutral rating on shares of Regeneron Pharmaceuticals buy says the stock's risk/reward is improved following the recent sharp pullback. The analyst adds that feedback from five doctors supports his above-consensus estimates for Dupixent. Kasimov currently models peak sales north of $7B across atopic dermatitis, asthma, and nasal polyps in the U.S. and Europe, "with everything else left as upside." Every $1B in total Dupixent revenue results in a $20 impact to the stock's fair valuation, the analyst tells investors in a research note titled "Dupi...How Big Is Big?"
News For REGN From the Last 2 Days